Loading
Masimo Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Aug 2025.
Masimo Corp: what insiders have been doing
Masimo Corp, classified in the Healthcare & Pharma sector, is a listed company based in Irvine. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Masimo Corp logged 8 filings by 5 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
There has been no open-market purchase by an insider of Masimo Corp for at least a year. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 8 filings here. Since 2021, the database holds 8 purchases and 11 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 3 January 2026 lists revenue at 1.53 bn USD and net income at -151.5 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€3M
8 ops. · all time
Sell Volume
€19M
11 ops. · all time
Who traded when
BuySaleCraig B. Reynolds1 sale
Michelle Brennan1 buy
William R. Jellison1 buy
Since the insiders bought
- -23.5%Entry US$164.55 · Close at T+365 US$125.94
- -34.9%Entry US$215.60 · Close at T+365 US$140.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Masimo Corp Hold (neutral), based on 3 analysts. Average price target: US$180.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,791 of 24,148 companies
44.7
score / 100
Value30
Quality60
FCF yld2.0%
Earn yld-1.6%
EV/EBITDA29.0x
ROE25%
Gross mgn62%
Net mgn-9.9%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$179.95
Analyst consensus
3 analystsHold
US$180.00Target US$180.00(+0%)US$180.00
Income statement
RevenueUS$1.5B
Gross profitUS$945.2M62% margin
EBITDAUS$344.6M23% margin
Net income-US$151.5M4.9% margin
Valuation
PER (trailing)44.4x
PER (forward)26.9x
P/Book11.9x
Beta1.10
Balance sheet & cash
Market capUS$9.4B
Total debtUS$559.3M
Free Cash FlowUS$193.1M
Debt / Equity62%
Profitability & ownership
ROE25.0%
ROA10.2%
% insiders6.2%
% institutions104.8%
Last declaration on 12 June 2026
Declarations83 total
9,309 sharesCommon StockSEC:0001104659-26-073526:0
2,101 shares0Common StockSEC:0000937556-26-000044:0
873 shares0Common StockSEC:0000937556-26-000042:0
15,000 shares0Common StockSEC:0000937556-26-000021:0
2,034 shares0Common StockSEC:0000937556-26-000019:0
11,141 shares@ US$132.96100.0% of flowCommon StockSEC:0000937556-26-000010:0
30,000 shares@ US$37.84100.0% of flowCommon StockSEC:0000937556-26-000008:0
2,474 shares@ US$152.43100.0% of flowCommon StockSEC:0000937556-25-000166:0
15,000 shares@ US$142.13100.0% of flowCommon StockSEC:0000937556-25-000142:0
126,888 shares0Common Stock, par value $0.001 per shareSEC:0001104659-25-085646:0
100 shares@ US$150.35100.0% of flowCommon StockSEC:0000937556-25-000125:0
Canonical exit: 10 Nov 2025 (T+90)
3,000 shares@ US$145.98100.0% of flowCommon StockSEC:0000937556-25-000123:0
Canonical exit: 9 Nov 2025 (T+90)
10,000 shares@ US$34.5122.9% of flowCommon StockSEC:0000937556-25-000084:0
1,790 shares0Common StockSEC:0000937556-25-000069:0
1,790 shares0Common StockSEC:0000937556-25-000075:0
1,383 shares0Common StockSEC:0000937556-25-000071:0
1,383 shares0Common StockSEC:0000937556-25-000073:0
1,790 shares0Common StockSEC:0000937556-25-000062:0
1,790 shares0Common StockSEC:0000937556-25-000066:0
1,790 shares0Common StockSEC:0000937556-25-000060:0
1,790 shares0Common Stock, par value $0.001 per shareSEC:0001104659-25-043642:0
2,053 shares@ US$166.131519.1% of flowCommon StockSEC:0000937556-25-000052:0
30,000 shares@ US$37.8477.1% of flowCommon StockSEC:0000937556-25-000045:0
15,000 shares0Common StockSEC:0000937556-25-000043:0
15,000 shares0Common StockSEC:0000937556-25-000039:0
25 of 83 declarations
About Masimo Corp
Masimo Corp. (ticker: MASI) is a U.S.-based medical technology company listed on the NASDAQ in the United States and headquartered in Irvine, California. Founded in 1989 by Joe Kiani as a private garage start-up, Masimo has evolved into a global leader in noninvasive patient monitoring, with more than 7,000 employees worldwide. The company’s core franchise centers on physiological monitoring technologies, especially pulse oximetry, but its portfolio has expanded well beyond that initial breakthrough into a broader platform for hospital automation, connectivity, and telehealth. ([masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai))
Masimo’s competitive position is built on clinically validated innovation and strong penetration in high-acuity care settings. The company highlights its SET® technology as the first “measure-through motion and low perfusion” pulse oximetry, designed to deliver reliable readings in difficult clinical conditions. That performance positioning has been a key differentiator in the company’s brand and commercial strategy, helping support adoption by leading hospitals and by OEM partners that embed Masimo technology in third-party monitoring devices. ([masimo.com](https://www.masimo.com/company/about/?utm_source=openai))
Read moreShow less
From a product perspective, Masimo offers sensors, patient monitors, connectivity modules, automation solutions, and advanced monitoring tools such as rainbow® pulse CO-oximetry, SedLine® brain function monitoring, O3® regional oximetry, and capnography. The Root® platform is an important part of the company’s ecosystem because it is designed to combine multiple Masimo and third-party monitoring capabilities in a modular architecture. This broader platform approach allows Masimo to serve operating rooms, ICUs, emergency care, and selected home-care or remote-monitoring use cases. ([masimo.com](https://www.masimo.com/products/sensors/brain-monitoring/sedline/?utm_source=openai))
Geographically, Masimo retains a strong U.S. operational base in Irvine while selling globally. The company presents itself as a worldwide medical technology provider whose solutions are intended to improve outcomes, streamline workflows, and extend noninvasive monitoring into new sites of care. Its international reach is supported both by direct commercialization and by licensing relationships with major medtech manufacturers. ([masimo.com](https://www.masimo.com/company/masimo/about/?utm_source=openai))
Recent developments are especially material for investors. In 2025, Masimo reported quarterly results and continued to advance new clinical evidence and FDA-cleared product enhancements, including updates for O3® regional oximetry. The most significant headline in 2026 is Masimo’s announced agreement to be acquired by Danaher for $180.00 per share in cash, implying total consideration of $9.9 billion, subject to customary closing conditions. For equity investors following SEC Form 4 insider activity, that transaction context is important because it frames the stock around event-driven M&A dynamics rather than purely standalone operating performance. ([masimo.com](https://www.masimo.com/media/masimo-to-be-acquired-by-danaher?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
